The results of a recently published national survey - co-authored by several HOPA members - have helped paint a clearer picture of the current landscape of oncology stewardship in the United States.

In order to gain greater knowledge about the state of oncology stewardship, HOPA distributed a survey to 675 of its members between September 9, 2022 and October 9, 2022. The survey results found that, though most organizations have adopted general oncology stewardship practices, significantly fewer have established formalized oncology stewardship programs due to a number of frequently cited barriers. The article concludes with a call for formalized oncology stewardship programs in the United States that aid in the value, quality, and safety of cancer care.

The full results of the national survey are now published in the Journal of Oncology Pharmacy Practice.


Authors: Marisela Tan Banez, Sol Atienza, Allison Butts, Megan Derba, Katie Dicke, Kimberly Haverstick, Bernadette B. Heron, Sarah K. Cimino, Matthew Shane Loop, Shannon Hough, Julianna A. Merten, Donald C. Moore, Vishal Shah, Kate D. Taucher, Junyu Matt Zhang, and Zahra Mahmoudjafari.

Read the full abstract here

An image of pancreatic cancer
HOPA News Late Breaking News

Late-Breaking HOPA News: RASolute 302 Breakthrough in Metastatic Pancreatic Adenocarcinoma

Michael Arnold, PharmD, discusses the very encouraging results from the RASolute 302 trial, a potential breakthrough in pancreatic cancer threapy.

Blood stem cells
HOPA News Late Breaking News

Late-Breaking HOPA News: Precision-T: Orca-T and the Evolution of GVHD Prophylaxis in Allogeneic Transplantation

Nathan Schieldt, PharmD, BCOP, discusses allogeneic hematopoietic stem cell transplantation's place as a potentially curative therapy for high-risk hematologic malignancies and how Orca-T provides a novel approach to allo-HSCT.

An image of multiple myeloma cells
HOPA News Late Breaking News

Late-Breaking HOPA News: Redefining Relapse: What MajesTEC-3 Means for the Treatment of Multiple Myeloma

Sanja Zepcan, PharmD, BCPS, BCOP, and Emily Rux, PharmD, BCOP, discuss the clinical questions raised by the recent MajesTEC-3 trial and the potential changes it finds in the treatment of multiple myeloma.